Taipei, Taiwan, 10 February 2026 — Lotus Pharmaceutical Co., Ltd. (Taiwan Stock Exchange: 1795), a global pharmaceutical leader based in Taiwan, today announced its unaudited consolidated revenues for January 2026 of NT$2,052 million, representing a decrease of 6% YoY. The decrease mainly reflected the absence of Lenalidomide sales, which had represented a substantial portion of Lotus’ revenue in the same period last year. Following the consolidation of Alvogen US, its revenue replaced a majority of Lotus’ export revenue. However, adverse weather conditions in January have temporarily disrupted shipments of several key products in the United States, impacting Alvogen US revenue. Shipments are expected to resume in February once conditions normalise.
Lotus’ Asia business grew 13% YoY in January 2026, mainly driven by Southeast Asian markets that saw a growth of 67%YoY as a result of Alpha Choay, which was consolidated in February 2025. Asia was also supported by Korea’s 6% YoY increase.
About Lotus
Founded in 1966, Lotus (1795: TT) is an international pharmaceutical company with a global presence, focused on commercializing both novel and generic pharmaceuticals to provide patients with better, safer, and more accessible medicines. The company boasts a best-in-class R&D and manufacturing platform in Asia, certified by leading regulatory authorities around the world, including the US FDA, EU EMA, Japan PMDA, China FDA, and Brazil ANVISA. Lotus has established partnerships in nearly every major global market, including the U.S., Europe, Japan, China, and Brazil. The company is currently developing and registering over 100 strategically selected pharmaceutical projects across Asia and the U.S., with more than 250 commercial products. Lotus invests in a diversified portfolio, consisting of high-barrier oncology, complex generics, 505(b)2, NCEs, and biosimilars, through both internal R&D investments and licensing-in partnerships to strengthen its portfolio competitiveness
Media Inquiries:
Yihsuan Kuo, Investor Relations Assistant Manager
Jeffrey Tsang, Head of Investor Relations and Corporate Communications
+886 2 2700 5908
investor@lotuspharm.com